Group 1 - The core point of the article is that Frontier Biotech has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small interfering RNA (siRNA) pipeline products, granting GSK global rights for development, manufacturing, and commercialization [1] - One of the candidate drugs has entered the Investigational New Drug (IND) application stage, while the other is in the preclinical stage [1] - Frontier Biotech will receive an upfront payment of $40 million and a near-term milestone payment of $13 million, with potential additional payments of up to $950 million based on successful development, regulatory, and commercialization milestones [1] Group 2 - Frontier Biotech will be responsible for early development work on the two products, including advancing one product through Phase I clinical trials in China and completing IND supportive research for the other product [1] - GSK will handle all global clinical development, regulatory submissions, and commercialization activities for both products [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 康希諾生物股份公司 Xuefeng YU 自願公告 董事長 曼海欣®獲 得《藥 品 補 充 申 請 批 准 通 知 書》 本 公 告 由 康 希 諾 生 物 股 份 公 司（「本公司」）自 願 作 出。 本 公 司 欣 然 宣 佈，本 公 司 已 獲 得 中 國 國 家 藥 品 監 督 管 理 局（「國家藥監局」）出 具 的《藥 品 補 充 申 請 批 准 通 知 書》，根 據 該 通 知 書，國 家 藥 監 局 已 批 准 本 公 司 的 ACYW135群 腦 膜 炎 球 菌 多 糖 結 合 疫 苗（CRM197載 體）（「MCV4」，商 品 名 稱：曼 海 欣®）的適用人群年齡範圍由「3月齡到3週歲（47月齡）兒童」擴大至「3月齡到6週歲（83 月 齡）兒 童」的 補 ...

Core Viewpoint - Sanofi Health (688336.SH) reported a significant increase in its 2025 annual performance, with total revenue reaching 4.199 billion yuan, a year-on-year increase of 251.81%, and a net profit attributable to shareholders of 2.939 billion yuan, up 317.09% [1] Financial Performance - The company achieved a net profit of 2.905 billion yuan after excluding non-recurring gains and losses, reflecting a staggering growth of 1041.01% [1] - Total assets at the end of the reporting period amounted to 8.887 billion yuan, an increase of 48.99% from the beginning of the year [1] - Shareholders' equity attributable to the parent company reached 8.457 billion yuan, growing by 51.89% compared to the start of the year [1] Revenue Drivers - The substantial growth in revenue and profit was primarily driven by a significant collaboration with Pfizer Inc., which included a licensing fee payment of approximately 2.890 billion yuan related to Project 707 [1]

Core Viewpoint - The company received approval from the National Medical Products Administration for an expanded age range for its ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier), now applicable for children aged 3 months to 6 years [1] Group 1 - The product, known as Manhaixin®, is the first quadrivalent meningococcal conjugate vaccine approved in China, which was launched in December 2021 [1] - The approval helps to narrow the gap between China and developed countries in the field of high-end vaccines, addressing the lack of such vaccines in the country [1] - Manhaixin® provides a superior solution for the prevention of meningococcal disease in children aged 6 years and below, demonstrating strong market performance and increasing market share [1]

营业总收入、营业利润、利润总额、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常 性损益的净利润、基本每股收益、总资产、归属于母公司的所有者权益以及归属于母公司所有者的每股 净资产相比上年同期均出现较大幅度的增长，该增长主要由于报告期内公司与辉瑞公司(PfizerInc.)达成 重要合作，公司收到辉瑞公司就707项目支付的授权许可首付款并相应确认收入约28.90亿元。 智通财经APP讯，三生国健(688336.SH)发布公告，2025年公司实现营业收入41.99亿元，较上年增加 251.81%。归属于母公司所有者的净利润29.39亿元，较上年涨幅317.09%。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary has received a drug registration certificate for a lyophilized human rabies vaccine from the National Medical Products Administration, marking a significant advancement in vaccine development in China [1] Group 1: Product Details - The vaccine utilizes the MRC-5 human diploid cell line recommended by the World Health Organization, demonstrating excellent safety, immunogenicity, and durability of immunity, particularly suitable for immunocompromised populations such as allergy sufferers, the elderly, and children [1] - This product is the first in China to cover three immunization schedules: "simplified 4-dose," "2-1-1," and "5-dose" regimens, showcasing its versatility in immunization protocols [1] Group 2: Regulatory Approval - The approval of the "simplified 4-dose" immunization schedule signifies a new breakthrough in the adaptability of human diploid cell rabies vaccines in China [1]

Core Viewpoint - Chengda Biological (688739.SH) has received a drug registration certificate from the National Medical Products Administration for its lyophilized human rabies vaccine, marking a significant advancement in vaccine development in China [1] Group 1: Product Development - The vaccine is developed using MRC-5 human diploid cells, which are derived from healthy human embryonic lung tissue, ensuring excellent safety, immunogenicity, and durability of immunity [1] - This product is the first in China to include three immunization schedules: "simple 4-dose," "2-1-1," and "5-dose," showcasing its adaptability to various immunization needs [1] Group 2: Market Implications - The approval of the "simple 4-dose" immunization schedule represents a breakthrough in the adaptability of human diploid rabies vaccines in China [1] - The diverse immunization programs allow the vaccine to cater to different exposure levels, time arrangements, and compliance rates, enhancing the overall completion rate of immunization and optimizing post-exposure prevention strategies [1] - The human diploid rabies vaccine possesses differentiated competitive advantages, which will enrich the company's product portfolio and better meet clinical demands [1]

Group 1 - The core issue raised by investors is the potential change in VAT collection method from 3% simplified taxation to 13% general taxation, and its expected impact on tax costs and company profits [1] - Shanghai Laishi responded that rare disease drugs within blood products will still be subject to the 3% simplified taxation, while other blood product businesses will no longer benefit from this rate, indicating a unified industry policy adjustment [1] - The company acknowledged that the adjustment will have a certain impact on the industry, but it plans to mitigate the effects through optimized procurement management and enhanced input tax deduction management [1]

2月24日，辉瑞中国与杭州先为达生物（以下简称先为达生物）宣布，双方就新一代偏向型GLP-1受体 激动剂埃诺格鲁肽注射液（英文：Ecnoglutide injection，以下简称：埃诺格鲁肽）达成商业化战略合作 协议。根据协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在中 国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、注 册、生产及供应。 先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付 款。埃诺格鲁肽是由先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，将为2型糖尿病及长 期体重管理相关患者提供更为精准的治疗方案。 ...

Core Insights - Frontline Bio has entered into an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small nucleic acid (siRNA) pipeline products, enhancing its global development and commercialization capabilities [1][2] - The agreement includes an upfront payment of $40 million and potential milestone payments totaling up to $950 million based on successful development and commercialization [1][2] - The collaboration is expected to improve Frontline Bio's cash flow and financial structure, providing solid funding for core pipeline research and technology platform upgrades [2][3] Company Summary - Frontline Bio will be responsible for early development work on the two products, including advancing one product through Phase I clinical trials in China and supporting IND research for the other [1] - GSK will handle all global clinical development, regulatory submissions, and commercialization activities for the products [1] - The partnership reflects growing recognition of Frontline Bio's research capabilities in the small nucleic acid drug development field [2][3] Industry Context - Small nucleic acid drugs are a significant development direction in the global pharmaceutical industry, offering precise gene silencing and durable, highly specific efficacy [3] - The market for small nucleic acid therapies is expanding from rare diseases to chronic conditions such as cardiovascular and metabolic diseases, indicating a broad market potential [3]